A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases

Yasuhiro Fujiwara; Yoshio Naomoto; Shunsuke Tanabe; Kazufumi Sakurama; Kazuhiro Noma; Toshio Nishikawa; Takayuki Motoki; Munenori Takaoka; Yasuhiro Shirakawa; Tomoki Yamatsuji; Junji Matsuoka; Noriaki Tanaka

A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases

Yasuhiro Fujiwara, Yoshio Naomoto, Shunsuke Tanabe, Kazufumi Sakurama, Kazuhiro Noma, Toshio Nishikawa, Takayuki Motoki, Munenori Takaoka, Yasuhiro Shirakawa, Tomoki Yamatsuji, Junji Matsuoka, Noriaki Tanaka

研究成果 › 査読

抄録

We report a case of a woman in her sixties having primary duodenal carcinoma with multiple liver metastases who was treated with oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX regimen). After completing 2 courses of the chemotherapy, computed tomography showed a partial response without any severe adverse events. Now at 8 months, the PR stage has been maintained. So far, no standard therapeutic strategy for metastatic duodenal carcinoma has been developed. However, we suggest a FOLFOX regimen can be highly effective as a safe approach for continuously maintaining the quality of life of patients with this rare type of cancer.

本文言語	English
ページ（範囲）	655-657
ページ数	3
ジャーナル	Japanese Journal of Cancer and Chemotherapy
巻	36
号	4
出版ステータス	Published - 4月 2009

ASJC Scopus subject areas

腫瘍学
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

他のファイルとリンク

引用スタイル

@article{a42b1c639a30455191e786d2c1faf4e0,

title = "A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases",

abstract = "We report a case of a woman in her sixties having primary duodenal carcinoma with multiple liver metastases who was treated with oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX regimen). After completing 2 courses of the chemotherapy, computed tomography showed a partial response without any severe adverse events. Now at 8 months, the PR stage has been maintained. So far, no standard therapeutic strategy for metastatic duodenal carcinoma has been developed. However, we suggest a FOLFOX regimen can be highly effective as a safe approach for continuously maintaining the quality of life of patients with this rare type of cancer.",

keywords = "FOLFOX, Liver metastasis, Primary duodenal carcinoma",

author = "Yasuhiro Fujiwara and Yoshio Naomoto and Shunsuke Tanabe and Kazufumi Sakurama and Kazuhiro Noma and Toshio Nishikawa and Takayuki Motoki and Munenori Takaoka and Yasuhiro Shirakawa and Tomoki Yamatsuji and Junji Matsuoka and Noriaki Tanaka",

year = "2009",

month = apr,

language = "English",

volume = "36",

pages = "655--657",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "4",

}

TY - JOUR

T1 - A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases

AU - Fujiwara, Yasuhiro

AU - Naomoto, Yoshio

AU - Tanabe, Shunsuke

AU - Sakurama, Kazufumi

AU - Noma, Kazuhiro

AU - Nishikawa, Toshio

AU - Motoki, Takayuki

AU - Takaoka, Munenori

AU - Shirakawa, Yasuhiro

AU - Yamatsuji, Tomoki

AU - Matsuoka, Junji

AU - Tanaka, Noriaki

PY - 2009/4

Y1 - 2009/4

N2 - We report a case of a woman in her sixties having primary duodenal carcinoma with multiple liver metastases who was treated with oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX regimen). After completing 2 courses of the chemotherapy, computed tomography showed a partial response without any severe adverse events. Now at 8 months, the PR stage has been maintained. So far, no standard therapeutic strategy for metastatic duodenal carcinoma has been developed. However, we suggest a FOLFOX regimen can be highly effective as a safe approach for continuously maintaining the quality of life of patients with this rare type of cancer.

AB - We report a case of a woman in her sixties having primary duodenal carcinoma with multiple liver metastases who was treated with oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX regimen). After completing 2 courses of the chemotherapy, computed tomography showed a partial response without any severe adverse events. Now at 8 months, the PR stage has been maintained. So far, no standard therapeutic strategy for metastatic duodenal carcinoma has been developed. However, we suggest a FOLFOX regimen can be highly effective as a safe approach for continuously maintaining the quality of life of patients with this rare type of cancer.

KW - FOLFOX

KW - Liver metastasis

KW - Primary duodenal carcinoma

UR - http://www.scopus.com/inward/record.url?scp=79959844802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959844802&partnerID=8YFLogxK

M3 - Article

C2 - 19381042

AN - SCOPUS:79959844802

SN - 0385-0684

VL - 36

SP - 655

EP - 657

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 4

ER -

A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases

抄録

ASJC Scopus subject areas

UN SDG

他のファイルとリンク

フィンガープリント

引用スタイル